ACET 最新10-Q变化

相对上期新增的文字 · 来源:10-Q · 2026-08-05

• In October 2025, we announced positive preliminary results from seven SLE and LN patients dosed in our ongoing Phase 1 trial of prula-cel in autoimmune diseases as of the August 31, 2025 data cut-off date. We plan to provide a comprehensive clinical update for this trial in LN and SLE patients in th…

• regulatory clearance. The Company plans to provide more details on the potential pivotal trial design in the third quarter of 2026. In addition, in the second half of 2026 we expect to report data evaluating prula-cel in patients with SSc.

• The Company is developing a differentiated in vivo CAR-T platform and pipeline targeting hematologic malignancies and solid tumors. A comprehensive update on the platform and pipeline is anticipated in the second half of 2026.

• The following table summarizes our results of operations for the periods indicated (in thousands, except percentages):

• Costs incurred under agreements with consultants, CDMOs, and CROs

相对上期删除的文字 · 来源:10-Q · 2026-05-13

• In October 2025, we announced positive preliminary results from seven SLE and LN patients dosed in our ongoing Phase 1 trial of prula-cel in autoimmune diseases as of the August 31, 2025 data cut-off date. We plan to meet with the FDA in the second quarter of 2026 to inform potential pivotal trial d…

• minimum of six months of follow up, with an additional update in the second half of 2026. We expect to provide a clinical update in patients with SSc in the second half of 2026.

• Additional Early-Stage Programs (CAR and Other Technologies)

• Our pipeline also includes additional early-stage gamma delta T cell therapy programs for autoimmune diseases, hematological malignancies and solid tumors. Additionally, we have ongoing preclinical programs and activities focused on a differentiated in vivo CAR-T platform targeting heme malignancies…

• Comparison of the Three Months Ended March 31, 2026 and 2025

相对上期新增的文字 · 来源:10-Q · 2026-08-05

• Our assets are primarily monetary, consisting of cash, cash equivalents and short-term investments in treasury securities. Because of their liquidity, these assets are not directly affected by inflation. Since we intend to retain and continue to use our

• equipment, furniture, fixtures and office equipment, computer hardware and software and leasehold improvements, we believe that the incremental inflation related to replacement costs of such items will not materially affect our operations. Inflation generally affects us by increasing our cost of lab…

相对上期删除的文字 · 来源:10-Q · 2026-05-13

• Our assets are primarily monetary, consisting of cash, cash equivalents and short-term investments in treasury securities. Because of their liquidity, these assets are not directly affected by inflation. Since we intend to retain and continue to use our equipment, furniture, fixtures and office equi…

相对上期新增的文字 · 来源:10-Q · 2026-08-05

• We expect to incur significant expenditures for the foreseeable future, and we expect these expenditures to increase as we continue our research and development of, and seek regulatory approvals for, product candidates based on our gamma delta T cell platform, including prula-cel and ADI-212. Even i…

• to any payment obligations we may have under future arrangements with third parties, may have a substantial impact on our business, financial condition and profitability.

相对上期删除的文字 · 来源:10-Q · 2026-05-13

• We expect to incur significant expenditures for the foreseeable future, and we expect these expenditures to increase as we continue our research and development of, and seek regulatory approvals for, product candidates based on our gamma delta T cell platform, including prula-cel and ADI-212. Even i…

• we will continue to incur substantial research and development and other expenditures to develop and market additional product candidates. In addition, certain of our existing license and collaboration agreements require cash payments upon the achievement of milestone events, royalties and profit-sh…

相对上期新增的文字 · 来源:10-Q · 2026-08-05

• On August 3, 2026, Julie Maltzman, M.D. notified Adicet Bio, Inc. (the “Company”) of her resignation as Chief Medical Officer of the Company, effective August 14, 2026 (the “Effective Date”). Dr. Maltzman’s resignation was not the result of any disagreement with the Company or its Board of Directors…

• Dr. Lloyd Klickstein, M.D., Ph.D. has been appointed as the Company’s Interim Chief Medical Officer, effective August 3, 2026.

• Dr. Klickstein, age 69, has served as a member of our board of directors since August 2024. Dr. Klickstein has served as president and chief executive officer of Koslapp Therapeutics, Inc. since April 2024. From February 2021 to March 2024, Dr. Klickstein served as the founding chief executive offic…

• Dr. Klickstein and the Company have entered into a Consulting Agreement, dated August 5, 2026 (the “Consulting Agreement”), effective as of August 3, 2026, pursuant to which Dr. Klickstein has agreed to serve as interim Chief Medical Officer on a full-time basis during the term of the Consulting Agr…

• There are no other arrangements or understandings between Dr. Klickstein and any other persons pursuant to which Dr. Klickstein was appointed as interim Chief Medical Officer of the Company. There is no family relationship between Dr. Klickstein and any director or executive officer of the Company. …